Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer

Pancreatic cancer remains a clinical challenge, thus new therapies are urgently needed. The selective Wee1 inhibitor MK-1775 has demonstrated promising results when combined with DNA damaging agents, and more recently with CHK1 inhibitors in various malignancies. We have previously demonstrated that...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Lett
Glavni autori: Wang, Guan, Niu, Xiaojia, Zhang, Wenbo, Caldwell, J. Timothy, Edwards, Holly, Chen, Wei, Taub, Jeffrey W., Zhao, Lijing, Ge, Yubin
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282784/
https://ncbi.nlm.nih.gov/pubmed/25458954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2014.10.015
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items